- Home
- ZNTL vs ADAG Comparison
ZNTL vs ADAG Comparison
Compare ZNTL & ADAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZNTL
- ADAG
- Stock Information
- Founded
- ZNTL 2014
- ADAG 2011
- Country
- ZNTL United States
- ADAG China
- Employees
- ZNTL N/A
- ADAG N/A
- Industry
- ZNTL Biotechnology: Pharmaceutical Preparations
- ADAG Biotechnology: Pharmaceutical Preparations
- Sector
- ZNTL Health Care
- ADAG Health Care
- Exchange
- ZNTL Nasdaq
- ADAG Nasdaq
- Market Cap
- ZNTL 105.8M
- ADAG 90.8M
- IPO Year
- ZNTL 2020
- ADAG 2021
- Fundamental
- Price
- ZNTL $1.99
- ADAG $2.39
- Analyst Decision
- ZNTL Buy
- ADAG Strong Buy
- Analyst Count
- ZNTL 7
- ADAG 2
- Target Price
- ZNTL $8.46
- ADAG $7.00
- AVG Volume (30 Days)
- ZNTL 784.9K
- ADAG 105.9K
- Earning Date
- ZNTL 08-06-2025
- ADAG 08-12-2025
- Dividend Yield
- ZNTL N/A
- ADAG N/A
- EPS Growth
- ZNTL N/A
- ADAG N/A
- EPS
- ZNTL N/A
- ADAG N/A
- Revenue
- ZNTL $26,865,000.00
- ADAG $103,204.00
- Revenue This Year
- ZNTL N/A
- ADAG $9,789.15
- Revenue Next Year
- ZNTL N/A
- ADAG $29.92
- P/E Ratio
- ZNTL N/A
- ADAG N/A
- Revenue Growth
- ZNTL N/A
- ADAG N/A
- 52 Week Low
- ZNTL $1.01
- ADAG $1.33
- 52 Week High
- ZNTL $5.44
- ADAG $3.58
- Technical
- Relative Strength Index (RSI)
- ZNTL 78.59
- ADAG 59.95
- Support Level
- ZNTL $1.55
- ADAG $1.65
- Resistance Level
- ZNTL $1.70
- ADAG $2.50
- Average True Range (ATR)
- ZNTL 0.12
- ADAG 0.37
- MACD
- ZNTL 0.05
- ADAG 0.03
- Stochastic Oscillator
- ZNTL 91.43
- ADAG 77.89
About ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.
About ADAG Adagene Inc.
Adagene Inc is a platform-driven, clinical-stage biopharmaceutical company engaged in transforming the discovery and development of novel antibody-based cancer immunotherapies. It is principally engaged in research, development, and production of monoclonal antibody drugs for cancers. The company's platform is designed to generate therapeutic antibody candidates with functional epitopes and species cross-reactivity, as highlighted by the company's immunotherapy pipeline.